Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.370
-0.010 (-0.42%)
At close: Jul 18, 2025, 4:00 PM
2.300
-0.070 (-2.95%)
After-hours: Jul 18, 2025, 7:52 PM EDT
Aytu BioPharma Stock Forecast
Stock Price Forecast
The 2 analysts that cover Aytu BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $10, which forecasts a 321.94% increase in the stock price over the next year. The lowest target is $8 and the highest is $12.
Price Target: $10 (+321.94%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aytu BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 1 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 1 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Lake Street | Lake Street | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +237.55% | Jul 1, 2025 |
Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +406.33% | Jun 30, 2025 |
Maxim Group | Maxim Group | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +110.97% | Aug 9, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +743.88% | May 31, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $220 → $120 | Strong Buy | Maintains | $220 → $120 | +4,963.29% | Jul 21, 2022 |
Financial Forecast
Revenue This Year
72.27M
from 81.00M
Decreased by -10.78%
Revenue Next Year
78.55M
from 72.27M
Increased by 8.68%
EPS This Year
0.67
from -2.86
EPS Next Year
0.09
from 0.67
Decreased by -86.36%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
---|---|---|---|---|---|---|
High | 74.4M | 80.9M | 103.9M | |||
Avg | 72.3M | 78.5M | 101.0M | |||
Low | 69.4M | 75.5M | 97.0M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
---|---|---|---|---|---|---|
High | -8.2% | 11.9% | 32.3% | |||
Avg | -10.8% | 8.7% | 28.5% | |||
Low | -14.3% | 4.4% | 23.5% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | 0.69 | 0.09 | 0.69 |
Avg | 0.67 | 0.09 | 0.67 |
Low | 0.65 | 0.09 | 0.65 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | -86.0% | 654.9% |
Avg | - | -86.4% | 633.3% |
Low | - | -86.9% | 604.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.